As described in a recent position paper, the EORTC Brain Tumor Group has prioritized the development of this clinical trial because of the high unmet clinical need to find novel treatments for patients with recurrent meningioma, a highly expressed molecular target (i.e., SSTR2) with proven efficacy of a theranostic treatment ([177Lu]Lu-DOTATATE) in another tumor type (neuroendocrine tumors), and the lack of a relevant blood–brain or blood–tumor barrier (26). Here, SSTR2 is linked to neoplasm.